WeVote
Log In

Bill

Bill

SB 2751

340B drug discount program entities; remove distributor from prohibition of certain discriminating actions related to.

2025 Regular Session Introduced by Briggs Hopson

SB 2751 would remove distributors from anti-discrimination protections for 340B entities, allowing drug wholesalers to engage in actions previously barred.

Died In Committee
#publichealthandwelfare
0
WeVote Research Nonpartisan
Bill Summary · SB 2751

Summary — SB 2751 (2025)

Title: 340B drug discount program entities; remove distributor from prohibition of certain discriminating actions related to
Subject: Public Health and Welfare
Introduced: March 13, 2025
Status: Died In Committee (per bill record)

Purpose / Intent

SB 2751 would have amended state law governing prohibited discriminatory actions toward entities participating in the federal 340B drug discount program by removing “distributor” from the list of entities covered by that prohibition. In other words, where current state statute prevents certain actors from discriminating against 340B-covered entities, this bill sought to carve distributors (wholesalers/intermediary drug distributors) out of that protection.

Key provisions (based on bill title and summary information)

  • Modify existing statutory language that prohibits specified discriminatory practices against 340B entities so that it no longer applies to “distributors.”
  • Leave intact the prohibitions as they apply to other named actors (manufacturers, pharmacies, payers, PBMs, etc.) unless the full text indicates otherwise.
  • The bill’s text was not provided in the materials; the description above is derived from the bill title and legislative summary line.

Who would be affected

  • 340B-covered entities: safety-net hospitals, federally qualified health centers (FQHCs), rural health clinics, and contract pharmacies that rely on 340B discounts. Removing distributors from the prohibition could change their ability to access product, pricing practices, allocation during shortages, or contract terms with distributors.
  • Drug distributors/wholesalers: would gain statutory latitude to engage in actions that might previously have been considered prohibited discrimination toward 340B entities.
  • Manufacturers, pharmacies, PBMs, payers and patients: could experience indirect effects through supply-chain or contracting changes (availability, formulary placement, pass-through pricing, administrative processes).
  • State regulators and enforcement entities: could see changed enforcement scope and fewer statutory tools to address distributor conduct toward 340B entities.

Potential impacts and considerations

  • Access & operations: In practice, allowing distributors to be excluded from anti‑discrimination rules could affect drug availability, ordering allocations, shipping practices, or fees charged to 340B entities.
  • Program integrity and costs: Changes could either raise administrative burdens or alter purchasing costs for covered entities; effects will depend on distributor behavior and any contract or market responses.
  • Unclear fiscal impact: No appropriation, dollar amounts, or fiscal analyses were provided in the available materials.

Procedural / timeline notes

  • Introduced and filed: March 13, 2025.
  • Legislative activity shows significant action in May 2025, including passage in the Senate (readings, suspension of three-day rule, reported engrossed, and other entries dated May 14–16, 2025) and referrals to House committees (Public Education; Education K‑16).
  • The bill record also lists “Died In Committee” (date shown as February 4, 2025). The legislative action chronology appears internally inconsistent; based on the record, the bill received committee consideration and further floor action but the official status is listed as Died In Committee. Consult the legislature’s official bill status page or the bill text for final disposition and exact amendments.

Note: Full bill text was not provided. For precise statutory language changes, enforcement mechanisms, and any exceptions or definitions, review the enrolled bill or legislative version posted by the legislature.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.